These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. HOPE for cardiovascular disease prevention with ACE-inhibitor ramipril. Heart Outcomes Prevention Evaluation. Kleinert S Lancet; 1999 Sep; 354(9181):841. PubMed ID: 10485736 [No Abstract] [Full Text] [Related]
43. Best bang for the buck? Weder AB Curr Hypertens Rep; 2003 Feb; 5(1):3-5. PubMed ID: 12530929 [No Abstract] [Full Text] [Related]
44. ACE inhibitor reduces cardiovascular events by 22%. Indian J Med Sci; 2000 Mar; 54(3):112-4. PubMed ID: 11227615 [No Abstract] [Full Text] [Related]
45. HOPE for all people with diabetes? Heart Outcomes Prevention Evaluation. Marshall SM Diabet Med; 2000 Sep; 17 Suppl 2():9-10. PubMed ID: 11048826 [No Abstract] [Full Text] [Related]
46. Should the results of the HOPE study affect nephrological practice? For the HOPE investigators. Mann JF Nephrol Dial Transplant; 2000 Apr; 15(4):453-4. PubMed ID: 10727536 [No Abstract] [Full Text] [Related]
48. Comparative effectiveness of angiotensin-converting-enzyme inhibitors: is an ACE always an ace? Hernandez AF; Harrington RA CMAJ; 2008 May; 178(10):1316-9. PubMed ID: 18458264 [No Abstract] [Full Text] [Related]
49. [Comprehensive organoprotection in patients with high cardiovascular risk: the possibility of ramipril from positions of evidence-based medicine]. Gaĭsenok OV; Marcevich SIu; Belolipetskaia VG Kardiologiia; 2013; 53(9):90-4. PubMed ID: 24090393 [TBL] [Abstract][Full Text] [Related]
50. The kidney in cardiovascular disease. Kasiske BL Ann Intern Med; 2001 Apr; 134(8):707-9. PubMed ID: 11304109 [No Abstract] [Full Text] [Related]
53. HOPE for diabetes in the new millennium. Heart Outcomes Prevention Evaluation. Donnelly R Diabetes Obes Metab; 2000 Jan; 2(1):1-2. PubMed ID: 11220348 [No Abstract] [Full Text] [Related]
54. The HOPE study and diabetes. Heart Outcomes Prevention Evaluation. Lewis V; Kloer P; Prasad N; Alcolado JC Lancet; 2000 Apr; 355(9210):1182; author reply 1183-4. PubMed ID: 10791399 [No Abstract] [Full Text] [Related]
55. Summaries for patients. Trial of a drug to decrease the risk for heart disease in patients with mild kidney failure. Ann Intern Med; 2001 Apr; 134(8):S-96. PubMed ID: 11324633 [No Abstract] [Full Text] [Related]
57. ACE-inhibition for secondary prevention of cardiovascular events--should we change our recommendation after PEACE? Ferrari R Cardiovasc Drugs Ther; 2006 Feb; 20(1):11-2. PubMed ID: 16649066 [No Abstract] [Full Text] [Related]
58. Do ACE inhibitors all provide the same outcomes benefits in high-risk cardiovascular patients? Lala A; McLaughlin MA Curr Hypertens Rep; 2008 Aug; 10(4):286-92. PubMed ID: 18625157 [TBL] [Abstract][Full Text] [Related]
59. The current role of ACE-inhibitors for secondary prevention in cardiovascular disease; from pathogenesis to clinical practice. Voors AA; van Veldhuisen DJ; van Gilst WH Cardiovasc Drugs Ther; 2006 Feb; 20(1):69-73. PubMed ID: 16619108 [No Abstract] [Full Text] [Related]
60. Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes. Nathan DM; Berkwits M Ann Intern Med; 2007 Mar; 146(6):461-3. PubMed ID: 17371892 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]